PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced the expansion of its “No Wash” ALPHA (Amplified Luminescent Proximity Homogeneous Assay) Technology portfolio. The Company is introducing 28 new highly sensitive cell signaling pathway and biomarker research assay kits, that provide researchers with rich data to help advance the study of diseases including cancer, inflammatory and neurodegenerative disorders.
The 28 new offerings include 9 AlphaScreen SureFire and 19 AlphaLISA “No-Wash” immunoassay kits, bringing the combined number of ALPHA-based kits to 174 assays.
“As scientific demand increases for sophisticated and robust methods for measuring cell signaling pathways and biomarkers for use in disease research, PerkinElmer remains at the forefront in meeting these critical needs,” said Richard Eglen, PhD, president, Bio-discovery, PerkinElmer. “Working closely with innovators in life sciences, PerkinElmer is proud to continue its leadership and commitment to customers by remaining the only provider of complete ALPHA Technology assay solutions, which are fully validated on the Company’s instrumentation to ensure optimal performance.”
